N-(3-hydroxypropyl)-3,4-dihydroxy-5-nitrobenzamide | 116314-83-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(3-hydroxypropyl)-3,4-dihydroxy-5-nitrobenzamide
• 英文别名: 3,4-dihydroxy-N-(3-hydroxypropyl)-5-nitrobenzamide
• CAS: 116314-83-1
• 化学式: C₁₀H₁₂N₂O₆
• 分子量: 256.215
• InChiKey: AJRXNFCZYZBKKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  136
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,4-diacetoxy-5-nitrobenzoic acid 、 3-氨基-1-丙醇 生成 N-(3-hydroxypropyl)-3,4-dihydroxy-5-nitrobenzamide
  参考文献：
  名称：

  Method of treating Parkinson's Disease using pentanedione derivatives

  摘要：

  本发明涉及一种治疗帕金森病的方法。该方法包括向患者施用一种具有以下式子I的化合物，其中R1和R2独立地表示氢、2至5个碳原子的烷基氨基酰基或2至5个碳原子的烷基羰基，X表示硝基或氰基，R3表示下列式子：其中R4表示氰基或2至5个碳原子的烷基羰基，R5表示氰基、2至5个碳原子的烷基羰基、未取代或取代了1至8个碳原子的烷基、1至8个碳原子的羟基烷基的氨基甲酰基或其药学上可接受的盐或酯；以及足够的左旋多巴治疗帕金森病。此外，最好还要施用周围脱羧酶抑制剂，如卡比多巴或苯扎酰胺。

  公开号：

  US05112861A1

文献信息

• Pharmacologically active compounds, methods for the preparation thereof
  申请人：Orion-yhtyma Oy

  公开号：US04963590A1

  公开（公告）日：1990-10-16

  Pharmacologically active catechol derivatives of formula I ##STR1## wherein R.sub.1 and R.sub.2 independently comprise hydrogen, alkyl, acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcabamoyl or taken together form a lower alkylidene or cycloalkylidene, X comprises an electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, aldehyde, caboxyl or trifluoromethyl and R.sub.3 comprises hydrogen, halogen, hydroxy alkyl, amino, nitro, cyano, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkyl carbonyl, aralkylidene carbonyl or carboxyl or a group selected from ##STR2## wherein R.sub.4 comprises hydrogen, alkyl, cyano, carboxyl or acyl and R.sub.5 comprises hydrogen, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, optionally substituted aroyl or heteroaroyl, hydroxyalkyl or carboxyalkyl or R.sub.4 and R.sub.5 together form a five to seven membered substituted cycloalkanone ring; --(CO).sub.n (CH.sub.2).sub.m --COR wherein n is 0-1 and m is 0-7 and R comprises hydroxy, alkyl, carboxyalkyl, optionally substituted alkene, alkoxy or optionally substituted amino; ##STR3## wherein R.sub.8 and R.sub.9 independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or together form an optionally substituted piperidyl group; --NH--CO--R.sub.10 wherein R.sub.10 comprises a substituted alkyl group.

  公式I的药理活性儿茶酚衍生物，其中R.sub.1和R.sub.2独立地包括氢、烷基、酰基、可选择地取代的芳酰基、较低的烷基磺酰基或烷基氨基甲酰基，或者一起形成较低的烷基亚甲基或环烷基亚甲基，X包括电负取代基，如卤素、硝基、氰基、较低的烷基磺酰基、磺胺基、醛基、羧基或三氟甲基，R.sub.3包括氢、卤素、羟基烷基、氨基、硝基、氰基、三
• Method of treating Parkinson's Disease using pentanedione derivatives
  申请人：Orion-yhtyma Oy

  公开号：US05112861A1

  公开（公告）日：1992-05-12

  The invention concerns a method for the treatment of Parkinson's Disease. The method comprises administering a catechol-O-methyl-transferase inhibiting amount of a compound having the formula I ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, alkylcarbamoyl of 2 to 5 carbon atoms or alkylcarbonyl of 2 to 5 carbon atoms, X represents nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents cyano; alkylcarbonyl of 2 to 5 carbon atoms; or carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, or hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable salts or esters thereof; and a sufficient amount of levodopa to treat Parkinson's Disease. A peripheral decarboxylase inhibitor such as carbidopa or benzerazide is also preferably administered.

  本发明涉及一种治疗帕金森病的方法。该方法包括向患者施用一种具有以下式子I的化合物，其中R1和R2独立地表示氢、2至5个碳原子的烷基氨基酰基或2至5个碳原子的烷基羰基，X表示硝基或氰基，R3表示下列式子：其中R4表示氰基或2至5个碳原子的烷基羰基，R5表示氰基、2至5个碳原子的烷基羰基、未取代或取代了1至8个碳原子的烷基、1至8个碳原子的羟基烷基的氨基甲酰基或其药学上可接受的盐或酯；以及足够的左旋多巴治疗帕金森病。此外，最好还要施用周围脱羧酶抑制剂，如卡比多巴或苯扎酰胺。
• Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation
  申请人：ORION-YHTYMÄ OY

  公开号：EP0444899A2

  公开（公告）日：1991-09-04

  Known and new catechol derivatives may be used as medicinal antioxidants in the prevention or treatment of tissue damage induced by lipid peroxidation. The conditions and diseases which may be treated are for example heart diseases, rheumatoid arthritis, cancer, inflammatory diseases, a rejection reaction in organ transplants, ischemia, cancer and aging.

  已知的和新的儿茶酚衍生物可用作药用抗氧化剂，用于预防或治疗脂质过氧化引起的组织损伤。可治疗的病症和疾病包括心脏病、风湿性关节炎、癌症、炎症性疾病、器官移植中的排异反应、缺血、癌症和衰老等。
• US4963590A
  申请人：——

  公开号：US4963590A

  公开（公告）日：1990-10-16
• US5112861A
  申请人：——

  公开号：US5112861A

  公开（公告）日：1992-05-12